Ocugen (OCGN) vs Relmada Therapeutics (RLMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Relmada Therapeutics (RLMD) has outperformed Ocugen (OCGN) over the past year, gaining 63.3% versus a loss of 43.2%. Over five years, RLMD leads with a -86.2% price change compared with -88.5% for OCGN. Relmada Therapeutics is the larger company by market cap ($331.7 million vs $331.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCGN | RLMD |
|---|---|---|
| Share price | $0.9765 | $3.11 |
| Market cap | $331.14M | $331.74M |
| 1-day change | -2.34% | -4.31% |
| YTD return | -25.93% | -32.71% |
| 1-year return | -43.18% | +63.32% |
| 5-year return | -88.45% | -86.25% |
| EPS (TTM) | $-0.26 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.73 | $8.00 |
| 52-week low | $0.9601 | $1.80 |
| Distance from 52-week high | -64.17% | -61.13% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1146.29% | +245.66% |
| Average volume | 5.81M | 1.33M |
| Shares outstanding | 339.11M | 106.67M |
| Employees | 116 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLMD has outperformed OCGN by 106.5 percentage points over the past year.
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 116 employees
About Relmada Therapeutics
RLMD stock →Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
OCGN vs RLMD FAQ
Which is bigger, Ocugen or Relmada Therapeutics?
Relmada Therapeutics (RLMD) is larger, with a market capitalization of $331.74M compared with $331.14M for Ocugen (OCGN).
Which stock has performed better over the past year, OCGN or RLMD?
RLMD returned +63.32% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are Ocugen and Relmada Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Ocugen and Biotechnology: Pharmaceutical Preparations for Relmada Therapeutics.